PT - JOURNAL ARTICLE AU - Minhphuong Nguyen AU - Eric Paul AU - Paul K. Mills AU - Simon Paul TI - Risk of COVID-19 Reinfection and Vaccine Breakthrough Infection, Madera County, California, 2021 AID - 10.1101/2022.01.22.22269105 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.22.22269105 4099 - http://medrxiv.org/content/early/2022/01/23/2022.01.22.22269105.short 4100 - http://medrxiv.org/content/early/2022/01/23/2022.01.22.22269105.full AB - The probability of either testing COVID-19 positive or dying for three cohorts in Madera County, California in 2021 was compared. These cohorts included 1. those unvaccinated, 2. those vaccinated and 3. persons with a previous COVID-19 infection. The three groups were made generally comparable by matching on age, gender, postal zip code of residence, and the date of either COVID-19 infection or of vaccination.The hazard ratio (HR) for death (from all causes) after COVID-19 infection vs. vaccination was 11.7 (95% CI 5.91-23.1, p<0.05). The HR for testing positive for COVID-19 >14 days after initial COVID-19 infection or after completing primary COVID-19 vaccination was 1.98 (95% CI 1.53-2.58 p<0.001). As the majority of positive COVID-19 tests in the post COVID-19 cohort occurred within 90 days of the initial infection, and as these early positives may not represent a new infection, we also compared rates of testing COVID-19 positive ≥ 90 days after initial infection or vaccination. After removing these early positive COVID-19 tests that occurred between days 14-90, the HR ratio for testing COVID-19 positive is now lower for the post COVID-19 cohort compared with the vaccinated cohort. The risk for having a positive COVID-19 test occurring 90 days after an initial COVID-19 infection or after vaccination was 0.54 (95% CI 0.33-0.87, p<0.05) for the post COVID-19 group vs Vaccinated group.Thus the risk for testing COVID-19 positive was higher in the first 90 days after COVID-19 infection compared to those vaccinated. However, from 90 to 300 days after COVID-19 infection, the post COVID-19 infection cohort had a lower risk of testing COVID-19 positive than those fully vaccinated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the County of Fresno, Department of Public Health Institutional Review Board, and was approved on January 20, 2022.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript